Efficacy Evaluation of “Enhanced” Natural Killers with CISH and B2M Knockouts on Viability and Metabolic Status of 3D Glioblastoma Spheroid Cells in Patients

One of the alternative approaches to glioblastoma treatment is cellular immunotherapy based on natural killer cells (NK cells). To enhance their cytotoxic effect on tumor cells, new NK cell lines are being created using genetic engineering techniques.

The aim of the study was to evaluate the impact efficacy of “enhanced” NK cells on early metabolic rearrangements and the viability of glioblastoma cells in a patient using a tumor spheroid model.

Materials and Methods. The study used a primary culture of GBM7-Luc2-mKate2 human glioblastoma, a line of YT (YTwt) wild-type human NK cells, as well as lines created by us with overexpression of VAV1 protein with either CISH (YT–Vav1⁺CISH^–/–) or B2M (YT–Vav1⁺B2M^–/–) knockouts. Tumor spheroids were produced in round-bottomed, low-adhesive plates. 100 thousand immune cells were added to each spheroid, and spheroids viability was evaluated at several time points applying fluorescence staining using a live/dead cell viability assay kit; autofluorescence of metabolic coenzyme nicotinamide adenine dinucleotide (phosphate), or NAD(P)H, was visualized in spheroids using an LSM 880 laser scanning microscope (Carl Zeiss, Germany) with a FLIM module (Becker & Hickl GmbH, Germany).

Results. It was found that autofluorescence attenuation parameters of NAD(P)H coenzyme in human glioblastoma cells change significantly when exposed to both YT–Vav1⁺CISH^–/– and YT–Vav1⁺B2M^–/–, indicating occurrence of an early metabolic shift in tumor cells towards a less aggressive oxidative phenotype, and this is consistent with dead cells fraction increase and living cells fraction decrease in spheroid composition.

Conclusion. The data obtained on enhanced cytotoxic activity of new modified NK cell lines against human glioblastoma spheroids are important to understand interaction mechanisms between tumor and immune cells and the development of glioblastoma adoptive cell therapy.

1. Lim M., Xia Y., Bettegowda C., Weller M. Current state of immunotherapy for glioblastoma. Nat Rev Clin Oncol 2018; 15(7): 422–442, https://doi.org/10.1038/s41571-018-0003-5.
2. Mahmoud A.B., Ajina R., Aref S., Darwish M., Alsayb M., Taher M., AlSharif S.A., Hashem A.M., Alkayyal A.A. Advances in immunotherapy for glioblastoma multiforme. Front Immunol 2022; 13: 944452, https://doi.org/10.3389/fimmu.2022.944452.
3. Liu Y., Zhou F., Ali H., Lathia J.D., Chen P. Immunotherapy for glioblastoma: current state, challenges, and future perspectives. Cell Mol Immunol 2024; 21(12): 1354–1375, https://doi.org/10.1038/s41423-024-01226-x.
4. Mamessier E., Sylvain A., Thibult M.L., Houvenaeghel G., Jacquemier J., Castellano R., Gonçalves A., André P., Romagné F., Thibault G., Viens P., Birnbaum D., Bertucci F., Moretta A., Olive D. Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest 2011; 121(9): 3609–3622, https://doi.org/10.1172/JCI45816.
5. Suen W.C., Lee W.Y., Leung K.T., Pan X.H., Li G. Natural killer cell-based cancer immunotherapy: a review on 10 years completed clinical trials. Cancer Invest 2018; 36(8): 431–457, https://doi.org/10.1080/07357907.2018.1515315.
6. Cooksey L.C., Friesen D.C., Mangan E.D., Mathew P.A. Prospective molecular targets for natural killer cell immunotherapy against glioblastoma multiforme. Cells 2024; 13(18): 1567, https://doi.org/10.3390/cells13181567.
7. Bryceson Y.T., Chiang S.C., Darmanin S., Fauriat C., Schlums H., Theorell J., Wood S.M. Molecular mechanisms of natural killer cell activation. J Innate Immun 2011; 3(3): 216–226, https://doi.org/10.1159/000325265.
8. da Silva L.H.R., Catharino L.C.C., da Silva V.J., Evangelista G.C.M., Barbuto J.A.M. The war is on: the immune system against glioblastoma-how can NK cells drive this battle? Biomedicines 2022; 10(2): 400, https://doi.org/10.3390/biomedicines10020400.
9. Malmberg K.J., Carlsten M., Björklund A., Sohlberg E., Bryceson Y.T., Ljunggren H.G. Natural killer cell-mediated immunosurveillance of human cancer. Semin Immunol 2017; 31: 20–29, https://doi.org/10.1016/j.smim.2017.08.002.
10. Yusubalieva G.M., Dashinimaev E.B., Gorchakov A.A., Kulemzin S.V., Brovkina O.A., Kalinkin A.A., Vinokurov A.G., Shirmanova M.V., Baklaushev V.P. Enhanced natural killers with CISH and B2M gene knockouts reveal increased cytotoxicity in glioblastoma primary cultures. Mol Biol 2022; 56: 770–779, https://doi.org/10.1134/S0026893322050156.
11. Chan G., Hanke T., Fischer K.D. Vav-1 regulates NK T cell development and NK cell cytotoxicity. Eur J Immunol 2001; 31(8): 2403–2410, https://doi.org/10.1002/1521-4141(200108)31:8<2403::aid-immu2403>3.0.co;2-o.
12. Delconte R.B., Kolesnik T.B., Dagley L.F., Rautela J., Shi W., Putz E.M., Stannard K., Zhang J.G., Teh C., Firth M., Ushiki T., Andoniou C.E., Degli-Esposti M.A., Sharp P.P., Sanvitale C.E., Infusini G., Liau N.P., Linossi E.M., Burns C.J., Carotta S., Gray D.H., Seillet C., Hutchinson D.S., Belz G.T., Webb A.I., Alexander W.S., Li S.S., Bullock A.N., Babon J.J., Smyth M.J., Nicholson S.E., Huntington N.D. CIS is a potent checkpoint in NK cell-mediated tumor immunity. Nat Immunol 2016; 17(7): 816–824, https://doi.org/10.1038/ni.3470.
13. Höglund P., Glas R., Ménard C., Kåse A., Johansson M.H., Franksson L., Lemmonier F., Kärre K. Beta2-microglobulin-deficient NK cells show increased sensitivity to MHC class I-mediated inhibition, but self tolerance does not depend upon target cell expression of H-2Kb and Db heavy chains. Eur J Immunol 1998; 28(1): 370–378, https://doi.org/10.1002/(SICI)1521-4141(199801)28:01%3C370::AID-IMMU370%3E3.0.CO;2-W.
14. Mitrakas A.G., Tsolou A., Didaskalou S., Karkaletsou L., Efstathiou C., Eftalitsidis E., Marmanis K., Koffa M. Applications and advances of multicellular tumor spheroids: challenges in their development and analysis. Int J Mol Sci 2023; 24(8): 6949, https://doi.org/10.3390/ijms24086949.
15. Shcheslavsky V.I., Shirmanova M.V., Eltsov A., Becker V. Luminescence microscopy based on multiparameter time-correlated photon counting. Uspekhi biologicheskoy khimii 2019; 59: 103–138.
16. Multimodal optical diagnostics of cancer. Tuchin V.V., Popp J., Zakharov V. (editors). Cham: Springer International Publishing; 2020.
17. Druzhkova I., Komarova A., Nikonova E., Baigildin V., Mozherov A., Shakirova Y., Lisitsa U., Shcheslavskiy V., Ignatova N., Shirshin E., Shirmanova M., Tunik S. Monitoring the intracellular pH and metabolic state of cancer cells in response to chemotherapy using a combination of phosphorescence lifetime imaging microscopy and fluorescence lifetime imaging microscopy. Int J Mol Sci 2023; 25(1): 49, https://doi.org/10.3390/ijms25010049.
18. Yuzhakova D.V., Sachkova D.A., Shirmanova M.V., Mozherov A.M., Izosimova A.V., Zolotova A.S., Yashin K.S. Measurement of patient-derived glioblastoma cell response to temozolomide using fluorescence lifetime imaging of NAD(P)H. Pharmaceuticals (Basel) 2023; 16(6): 796, https://doi.org/10.3390/ph16060796.
19. Yuzhakova D., Kiseleva E., Shirmanova M., Shcheslavskiy V., Sachkova D., Snopova L., Bederina E., Lukina M., Dudenkova V., Yusubalieva G., Belovezhets T., Matvienko D., Baklaushev V. Highly invasive fluorescent/bioluminescent patient-derived orthotopic model of glioblastoma in mice. Front Oncol 2022; 12: 897839, https://doi.org/10.3389/fonc.2022.897839.
20. Yuzhakova D.V., Lukina M.M., Sachkova D.A., Yusubalieva G.M., Baklaushev V.P., Mozherov A.M., Dudenkova V.V., Gavrina A.I., Yashin K.S., Shirmanova M.V. Development of a 3D tumor spheroid model from the patient’s glioblastoma cells and its study by metabolic fluorescence lifetime imaging. Sovremennye tehnologii v medicine 2023; 15(2): 28–38, https://doi.org/10.17691/stm2023.15.2.03.
21. Tao J.H., Zhang J., Li H.S., Zhou Y., Guan C.X. Nature killer cell for solid tumors: current obstacles and prospective remedies in NK cell therapy and beyond. Crit Rev Oncol Hematol 2025; 205: 104553, https://doi.org/10.1016/j.critrevonc.2024.104553.
22. Chu J., Gao F., Yan M., Zhao S., Yan Z., Shi B., Liu Y. Natural killer cells: a promising immunotherapy for cancer. J Transl Med 2022; 20(1): 240, https://doi.org/10.1186/s12967-022-03437-0.
23. Feldman L., Brown C., Badie B. Chimeric antigen receptor (CAR) T cell therapy for glioblastoma. Neuromolecular Med 2022; 24(1): 35–40, https://doi.org/10.1007/s12017-021-08689-5.
24. Rautela J., Huntington N.D. IL-15 signaling in NK cell cancer immunotherapy. Curr Opin Immunol 2017; 44: 1–6, https://doi.org/10.1016/j.coi.2016.10.004.
25. Ahmadzadeh M., Rosenberg S.A. IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 2006; 107(6): 2409–2414, https://doi.org/10.1182/blood-2005-06-2399.
26. Felices M., Lenvik A.J., McElmurry R., Chu S., Hinderlie P., Bendzick L., Geller M.A., Tolar J., Blazar B.R., Miller J.S. Continuous treatment with IL-15 exhausts human NK cells via a metabolic defect. JCI Insight 2018; 3(3): e96219, https://doi.org/10.1172/jci.insight.96219.
27. Lukina M.M., Dudenkova V.V., Shimolina L.E., Snopova L.B., Zagaynova E.V., Shirmanova M.V. In vivo metabolic and SHG imaging for monitoring of tumor response to chemotherapy. Cytometry A 2019; 95(1): 47–55, https://doi.org/10.1002/cyto.a.23607.
28. Lukina M.M., Dudenkova V.V., Ignatova N.I., Druzhkova I.N., Shimolina L.E., Zagaynova E.V., Shirmanova M.V. Metabolic cofactors NAD(P)H and FAD as potential indicators of cancer cell response to chemotherapy with paclitaxel. Biochim Biophys Acta Gen Subj 2018; 1862(8): 1693–1700, https://doi.org/10.1016/j.bbagen.2018.04.021.
29. Shirmanova M.V., Druzhkova I.N., Lukina M.M., Dudenkova V.V., Ignatova N.I., Snopova L.B., Shcheslavskiy V.I., Belousov V.V., Zagaynova E.V. Chemotherapy with cisplatin: insights into intracellular pH and metabolic landscape of cancer cells in vitro and in vivo. Sci Rep 2017; 7(1): 8911, https://doi.org/10.1038/s41598-017-09426-4.
30. Shah A.T., Demory Beckler M., Walsh A.J., Jones W.P., Pohlmann P.R., Skala M.C. Optical metabolic imaging of treatment response in human head and neck squamous cell carcinoma. PLoS One 2014; 9(3): e90746, https://doi.org/10.1371/journal.pone.0090746.
31. Alam S.R., Wallrabe H., Svindrych Z., Chaudhary A.K., Christopher K.G., Chandra D., Periasamy A. Investigation of mitochondrial metabolic response to doxorubicin in prostate cancer cells: an NADH, FAD and tryptophan FLIM assay. Sci Rep 2017; 7(1): 10451, https://doi.org/10.1038/s41598-017-10856-3.
32. Song A., Zhao N., Hilpert D.C., Perry C., Baur J.A., Wallace D.C., Schaefer P.M. Visualizing subcellular changes in the NAD(H) pool size versus redox state using fluorescence lifetime imaging microscopy of NADH. Commun Biol 2024; 7(1): 428, https://doi.org/10.1038/s42003-024-06123-7.
33. Zhao J., Ma X., Gao P., Han X., Zhao P., Xie F., Liu M. Advancing glioblastoma treatment by targeting metabolism. Neoplasia 2024; 51: 100985, https://doi.org/10.1038/s42003-024-06123-7.
34. Principles of fluorescence spectroscopy. Lakowicz J.R. (editor). Boston: Springer US; 2006.
35. Morrow C.S., Yao P., Vergani-Junior C.A., Anekal P.V., Llopis P.M., Miller J.W., Benayoun B.A., Mair W.B. Endogenous mitochondrial NAD(P)H fluorescence can predict lifespan. Commun Biol 2024; 7: 1551, https://doi.org/10.1038/s42003-024-07243-w.
36. Sanchez T., Wang T., Pedro M.V., Zhang M., Esencan E., Sakkas D., Needleman D., Seli E. Metabolic imaging with the use of fluorescence lifetime imaging microscopy (FLIM) accurately detects mitochondrial dysfunction in mouse oocytes. Fertil Steril 2018; 110(7): 1387–1397, https://doi.org/10.1016/j.fertnstert.2018.07.022.
37. Yang J., Shay C., Saba N.F., Teng Y. Cancer metabolism and carcinogenesis. Exp Hematol Oncol 2024; 13(1): 10, https://doi.org/10.1186/s40164-024-00482-x.
38. Heinrich M.A., Huynh N.T., Heinrich L., Prakash J. Understanding glioblastoma stromal barriers against NK cell attack using tri-culture 3D spheroid model. Heliyon 2024; 10(3): e24808, https://doi.org/10.1016/j.heliyon.2024.e24808.

Yuzhakova D.V., Sachkova D.A., Shirmanova M.V., Shcheslavskiy V.I., Mozherov A.M., Dashinimaev E.B., Baklaushev V.P., Yusubalieva G.M. Efficacy Evaluation of “Enhanced” Natural Killers with CISH and B2M Knockouts on Viability and Metabolic Status of 3D Glioblastoma Spheroid Cells in Patients. Sovremennye tehnologii v medicine 2025; 17(1): 109, https://doi.org/10.17691/stm2025.17.1.10